The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 1525-1531

  Gu, Namyi ^a   Cho, Joo Youn ^b   Shin, Kwang Hee ^c   Jang, In Jin ^b   Rhee, Moo Yong ^a  

^a Dongguk University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Aldosterone; Angiotensin receptor blocker; Cytochrome P450 3A4; Healthy; P glycoprotein; Renin; Renin activity; Sodium diet

Indexed keywords

ALDOSTERONE; CREATINE KINASE; CYTOCHROME P450 3A4; FIMASARTAN; MULTIDRUG RESISTANCE PROTEIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; PYRIMIDINE DERIVATIVE; RENIN; SODIUM INTAKE; TETRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALDOSTERONE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FATIGUE; HEADACHE; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PAPULE; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SODIUM INTAKE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADMINISTRATION AND DOSAGE; BLOOD; METABOLISM; MIDDLE AGED; PHARMACOLOGY; YOUNG ADULT;

ADULT; ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; RENIN; SODIUM, DIETARY; TETRAZOLES; YOUNG ADULT;

EID: 84964530062     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S94694     Document Type: Article

References (20)

1. Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA. Sodium restriction lowers high blood pressure through a decreased response of the renin system – direct evidence using saralasin. J Hypertens. 1985;3(3):243–247.
2. MacGregor GA, Markandu ND, Singer DR, Cappuccio FP, Shore AC, Sagnella GA. Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. Br Med J. 1987;294(6571):531–534.
3. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet. 1989;2(8674):1244–1247.
4. Singer DR, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension. 1995;25(5):1042–1044.
5. Fromm MF, Darbar D, Dell’Orto S, Roden DM. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ther. 1999;290(1):253–258.
6. Darbar D, Fromm MF, Dell’Orto S, et al. Modulation by dietary salt of verapamil disposition in humans. Circulation. 1998;98(24):2702–2708.
7. Darbar D, Dell’Orto S, Morike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther. 1997;61(3):292–300.
8. Kosuge K, Chuang AI, Uematsu S, et al. Discovery of osmosensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5). Mol Pharmacol. 2007;72(4):826–837.
9. Kang HJ, Song IS, Lee SS, Yoo MA, Shin JG. Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats. Xenobiotica. 2008;38(2):147–155.
10. Azizi M, Blanchard A, Charbit B, et al. Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. Hypertension. 2013;61(6):1239–1245.
11. Charytan DM, Forman JP. You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy. Kidney Int. 2012;82(3):257–259.
12. Kim JW, Yi S, Kim TE, et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. J Clin Pharmacol. 2013;53(1):75–81.
13. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, 55th WMA General Assembly, Tokyo 2004. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed April 4, 2015.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6 (R1). Step 4 version, ICH Harmonised Tripartite Guideline. 1996. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed April 2015.
15. Bonate PL, Howard D. Pharmacokinetics in Drug Development. Volume 1: Clinical Study Design and Analysis. Arlington, VA: American Association of Pharmaceutical Scientists; 2004.
16. Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005;43(10):485–498.
17. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs – General Considerations. Rockville, MD: Food and Drug Administration; 2014.
18. Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharm. 2011;57(6):682–689.
19. Chi YH, Lee H, Paik SH, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am J Cardiovasc Drugs. 2011;11(5):335–346.
20. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9–20.